Fig. 4

Hdac6 is dispensable for murine megakaryopoiesis. a, b Western blot analysis and quantification of Hdac6 and acetylated tubulin levels. c Platelet count in WT (n = 20) and hdac6^−/− (n = 10) mice. d Similar counts of MK number in the WT and Hdac6 KO bone marrows as attested after vWF staining. e Hdac6 knockout does not affect MK polyploidization in vivo. f Similar CFU-MK growth in WT and hdac6 KO mice. g Normal recovery of platelet count in WT and KO mice after thrombocytopenia induction by an anti-CD41 antibody. h Normal PPF from MKs isolated from WT and Hdac6 KO bone marrows. i, j. Western blot analysis and quantification of 48 h-treated MKs with both inhibitors showing a smaller IC50 compared to human MKs and an increase in histones H3 acetylation at 1 μM. k In vitro proplatelet formation by MKs treated with Tubastatin A or ACY1215. Unpaired Student’s t test, *p < 0.05; **p < 0.001; ***p < 0.0001. l A shRNA against murine hdac6 (sh-mHDAC6) has no effect on PPF in vitro. Results are representative of three independent experiments carried on at least three mice for each group (n = 3). Error bars in b, j, k, and l are SEM, error bars in c, d, f–h are SD